vxa-a1.1
Vaccineexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01688297)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vxa-a1.1
- vxa-a1.1 h1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03125473 | Phase 1 | Apr 7, 2017 | Celerion, Vaxart |
| NCT03121339 | Phase 1 | Mar 31, 2017 | Vaxart |
| NCT02918006 | Phase 2 | Aug 1, 2016 | Department of Health and Human Services, Vaxart |
| NCT02868073 | Phase 1 | Jul 1, 2016 | Celerion, Vaxart |
| NCT01761123 | Phase 1 | Jan 1, 2013 | Scintipharma, Vaxart |
| NCT01688297 | Phase 1 | Sep 1, 2012 | Vaxart, WCCT Global |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vaxart | For profit | 6 | 6 | 2 | 2012 |
| Celerion | For profit | 2 | 0 | 1 | 2016 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2016 |
| Scintipharma | For profit | 1 | 0 | 1 | 2013 |
| WCCT Global | For profit | 1 | 0 | 1 | 2012 |
5 organizations
Page 1 / 1